GAINESVILLE, FL – (BusinessWire) – May 19, 2020 – Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that it will hold a call for investors and the NPC community on Wednesday, May 20, 2020 at 4:30 pm EDT. “We look forward to speaking to the patient and investor communities about the data from our completed phase I clinical trial and our unblinded interim analysis of our Phase I/II clinical trial for our Trappsol® Cyclo™ product used in the treatment of Niemann-Pick Disease Type C,” said Cyclo Therapeutics’ Chairman and CEO, N. Scott Fine. “We have made great progress with encouraging results and are now moving toward a Phase III global pivotal trial as we continue our efforts to obtain marketing approval for this important treatment of a devastating disease.”
The call will be conducted using the Company’s Zoom webinar platform. Registration and connection details are at the following link:
https://zoom.us/webinar/register/WN_QaTtTZiJTQGRatotHsLnpg
Cyclo Therapeutics Clinical and Regulatory Update Call An opportunity to submit questions prior to the start of the webinar is available upon registration. This call will be recorded, and audio replay will be available on the company’s website shortly after the call concludes.
About Cyclo Therapeutics:
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three formal clinical trials for Niemann-Pick Disease Type C, a rare and often fatal genetic disease, (ClinicalTrials.gov NCT02939547, NCT02912793 and NCT03893071). The company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company’s website: www.cyclotherapeutics.com
Safe Harbor Statement:
This press release contains “forward-looking statements” about the company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company’s future performance include the company’s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company’s biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company’s filings with the Securities and Exchange Commission, including, but not limited to, the company’s reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
Investor/Media Contact:
Sitrick and Company
Mark Veverka
mveverka@sitrick.com
415-999-9634
